Ubelgiji - Kiholanzi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol 0,03 mg; levonorgestrel 0,15 mg - filmomhulde tablet - 30 µg - 150 µg - ethinylestradiol 30 µg; levonorgestrel 150 µg - levonorgestrel and ethinylestradiol

Ubelgiji - Kifaransa - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - désogestrel 150 µg; ethinylestradiol 30 µg - comprimé - 150 µg - 30 µg - désogestrel 150 µg; ethinylestradiol 30 µg - desogestrel and ethinylestradiol

Ubelgiji - Kifaransa - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol 0,03 mg; lévonorgestrel 0,15 mg - comprimé pelliculé - 30 µg - 150 µg - ethinylestradiol 30 µg; lévonorgestrel 150 µg - levonorgestrel and ethinylestradiol

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - buprenorphin - transdermales pflaster - 30 mikrogramm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 30 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 30 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 30 milligramm

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: hyprolose; purified talc; triethyl citrate; crospovidone; titanium dioxide; hypromellose phthalate; hypromellose; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: purified talc; crospovidone; titanium dioxide; hypromellose; triethyl citrate; hyprolose; hypromellose phthalate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: titanium dioxide; purified talc; hyprolose; hypromellose; hypromellose phthalate; crospovidone; triethyl citrate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Marekani - Kiingereza - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets usp have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets usp have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown. the optimal duration of clopidogrel tablet usp therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets usp ha